$CERO
CERo Therapeutics Holdings Inc Stock $cero

$cero Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-K Financial Statement

#000121390024029051 Filed on April 02, 2024

Income Statement

Concept	2024 Q2	2023 Q4	2023 Q3
Revenue		$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin		$369.3K	$430.0K
YoY Change		-71.31%	-48.61%
% of Gross Profit
Research & Development	$2.714M
YoY Change	127.51%
% of Gross Profit
Depreciation & Amortization	$114.3K
YoY Change	-0.94%
% of Gross Profit
Operating Expenses	$5.148M	$369.3K	$430.0K
YoY Change	233.53%	-71.31%	-48.61%
Operating Profit	-$5.148M		-$429.8K
YoY Change	233.53%		-48.63%
Interest Expense		$111.0K	$120.0K
YoY Change		-92.9%	-87.78%
% of Operating Profit
Other Income/Expense, Net	$2.700M
YoY Change	740.37%
Pretax Income		-$258.4K	-$308.3K
YoY Change		-193.62%	-312.65%
Income Tax		$24.40K	$25.75K
% Of Pretax Income
Net Earnings	-$2.449M	-$282.8K	-$334.0K
YoY Change	70.31%	7.66%	-495.28%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.15
Diluted Earnings Per Share	-$0.15	-$0.04	-$0.05
COMMON SHARES
Basic Shares Outstanding	14.72M shares
Diluted Shares Outstanding	16.20M shares

Balance Sheet

Concept	2024 Q2	2023 Q4	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments		$25.10M	$100.0K
YoY Change		5173.89%	-80.31%
Cash & Equivalents	$3.647M	$96.87K	$119.0K
Short-Term Investments		$25.00M
Other Short-Term Assets		$8.463M	$8.300M
YoY Change		-79.8%	2892.28%
Inventory
Prepaid Expenses
Receivables
Other Receivables	$87.43K
Total Short-Term Assets	$4.246M	$1.970M	$8.500M
YoY Change	-69.91%	-95.35%	982.4%
LONG-TERM ASSETS
Property, Plant & Equipment	$738.8K	$966.7K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$3.125M	$6.591M	-$29.38K
YoY Change	104161700.0%		-100.02%
TOTAL ASSETS
Total Short-Term Assets	$4.246M	$1.970M	$8.500M
Total Long-Term Assets	$3.125M	$6.591M	-$29.38K
Total Assets	$7.371M	$8.561M	$8.471M
YoY Change	-47.76%	-79.79%	-95.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.347M	$1.672M	$3.300M
YoY Change	101.76%	1.13%	364.56%
Accrued Expenses	$1.157M	$144.6K	$100.0K
YoY Change	5687.42%		-1.81%
Deferred Revenue
YoY Change
Short-Term Debt		$1.555M	$1.400M
YoY Change		139.23%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$8.779M	$5.173M	$4.801M
YoY Change	99.03%	-83.17%	448.04%
LONG-TERM LIABILITIES
Long-Term Debt		$0.00	$0.00
YoY Change
Other Long-Term Liabilities		$9.150M	$9.200M
YoY Change		0.0%	0.55%
Total Long-Term Liabilities		$9.150M	$9.200M
YoY Change		0.0%	0.55%
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.779M	$5.173M	$4.801M
Total Long-Term Liabilities		$9.150M	$9.200M
Total Liabilities	$9.853M	$14.32M	$13.95M
YoY Change	-27.35%	-64.1%	39.15%
SHAREHOLDERS EQUITY
Retained Earnings	-$67.36M	-$14.20M	-$13.77M
YoY Change	406.79%	29.08%
Common Stock	$0.00	$907.00
YoY Change	-100.0%	930.68%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$2.482M	-$14.20M	-$13.77M
YoY Change
Total Liabilities & Shareholders Equity	$7.371M	$8.561M	$8.471M
YoY Change	-47.76%	-79.79%	-95.31%

Cashflow Statement

Concept	2024 Q2	2023 Q4	2023 Q3
OPERATING ACTIVITIES
Net Income	-$2.449M	-$282.8K	-$334.0K
YoY Change	70.31%	7.66%	-495.28%
Depreciation, Depletion And Amortization	$114.3K
YoY Change	-0.94%
Cash From Operating Activities		-$186.6K	-$260.0K
YoY Change		-49.99%	49.13%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities		-$13.82M	$5.680M
YoY Change		-107.65%	4320.58%
Cash From Investing Activities		-$13.82M	$5.680M
YoY Change		-107.65%	4320.58%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		-27.68M	-5.420M
YoY Change		-80.04%
NET CHANGE
Cash From Operating Activities		-186.6K	-260.0K
Cash From Investing Activities		-13.82M	5.680M
Cash From Financing Activities		-27.68M	-5.420M
Net Change In Cash		-41.69M	0.000
YoY Change		-200.13%	-100.0%
FREE CASH FLOW
Cash From Operating Activities		-$186.6K	-$260.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits		usd
CY2022Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-40877
CY2023	dei	Entity Registrant Name EntityRegistrantName	CERO THERAPEUTICS HOLDINGS, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	81-4182129
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	201 Haskins Way
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 230
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	South San Francisco
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94080
CY2023	dei	City Area Code CityAreaCode	(215)
CY2023	dei	Local Phone Number LocalPhoneNumber	731-9450
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	2688948	usd
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	14723565	shares
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023	dei	Auditor Name AuditorName	Citrin Cooperman & Company, LLP
CY2023	dei	Auditor Location AuditorLocation	New York
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	96873	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	475870	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	27426	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	225188	usd
CY2023Q4	us-gaap	Assets Held In Trust Current AssetsHeldInTrustCurrent	8436311	usd
CY2022Q4	us-gaap	Assets Held In Trust AssetsHeldInTrust	41665974	usd
CY2023Q4	us-gaap	Assets Assets	8560610	usd
CY2022Q4	us-gaap	Assets Assets	42367032	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3535084	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1653120	usd
CY2023Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	23633	usd
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	599159	usd
CY2022Q4	cero	Shareholder Redemption Liability ShareholderRedemptionLiability	27842747	usd
CY2023Q4	cero	Excise Tax Payable ExciseTaxPayable	56389	usd
CY2023Q4	cero	Due To Affiliate DueToAffiliate	3315	usd
CY2022Q4	cero	Due To Affiliate DueToAffiliate	3315	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5173421	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	30748341	usd
CY2023Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	9150000	usd
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	9150000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	14323421	usd
CY2022Q4	us-gaap	Liabilities Liabilities	39898341	usd
CY2023Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	764957	shares
CY2022Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	1288298	shares
CY2023Q4	us-gaap	Temporary Equity Redemption Price Per Share TemporaryEquityRedemptionPricePerShare	11.03
CY2022Q4	us-gaap	Temporary Equity Redemption Price Per Share TemporaryEquityRedemptionPricePerShare	10.26
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	8436311	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	13468845	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-14199669	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-11000701	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-14199122	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-11000154	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8560610	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	42367032	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2892935	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2841391	usd
CY2023	us-gaap	Franchisor Costs FranchisorCosts	40050	usd
CY2022	us-gaap	Franchisor Costs FranchisorCosts	64050	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-2932985	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-2905441	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	491571	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	2836864	usd
CY2023	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	491571	usd
CY2022	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	2836864	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2441414	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-68577	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	94819	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	599159	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-2536233	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-667736	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-7669865	usd
CY2022	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	2662553	usd
CY2023	cero	Percentage Of Aggregate Share PercentageOfAggregateShare	0.20	pure
CY2023Q1	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	100000	usd
CY2023Q2	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	125000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-667736	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-11000154	usd
CY2023	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	606346	usd
CY2023	cero	Stock Issued During Period Value Excise Tax Payable StockIssuedDuringPeriodValueExciseTaxPayable	56389	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-2536233	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-14199122	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-2536233	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-667736	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	491571	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	2836864	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-197762	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-254831	usd
CY2023	us-gaap	Increase Decrease In Income Taxes IncreaseDecreaseInIncomeTaxes	-575526	usd
CY2022	us-gaap	Increase Decrease In Income Taxes IncreaseDecreaseInIncomeTaxes	599159	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1881964	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1638687	usd
CY2022	us-gaap	Increase Decrease In Property And Other Taxes Payable IncreaseDecreaseInPropertyAndOtherTaxesPayable	-80324	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1523604	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1092247	usd
CY2023	us-gaap	Proceeds From Sale Of Restricted Investments ProceedsFromSaleOfRestrictedInvestments	752300	usd
CY2022	us-gaap	Proceeds From Sale Of Restricted Investments ProceedsFromSaleOfRestrictedInvestments	144544	usd
CY2023	us-gaap	Payments To Acquire Trust Preferred Investments PaymentsToAcquireTrustPreferredInvestments	14335919	usd
CY2022	us-gaap	Payments To Acquire Trust Preferred Investments PaymentsToAcquireTrustPreferredInvestments	325000	usd
CY2023	us-gaap	Proceeds From Sale And Maturity Of Other Investments ProceedsFromSaleAndMaturityOfOtherInvestments	5638879	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Other Investments ProceedsFromSaleAndMaturityOfOtherInvestments	181019852	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7944740	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	180839396	usd
CY2023	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	905000	usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	650000	usd
CY2023	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	33481627	usd
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	139353878	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-32576627	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-138703878	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-42044971	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	41043271	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	42141844	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1098573	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	96873	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	42141844	usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid	670345	usd
CY2023	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	606346	usd
CY2022	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	2662553	usd
CY2022	cero	Shareholders Redemption Liability ShareholdersRedemptionLiability	27842747	usd
CY2023	cero	Conversion Of Class B Common To Class A Common ConversionOfClassBCommonToClassACommon	-459	usd
CY2023	cero	Excise Tax Liability Accrued For Class A Common Stock Redemptions ExciseTaxLiabilityAccruedForClassACommonStockRedemptions	56389	usd
CY2023	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	8450000	usd
CY2023	cero	Deferred Underwriting Fees DeferredUnderwritingFees	9150000	usd
CY2023	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	178500000	usd
CY2023Q4	cero	Cash Deposited In Trust Account Per Unit CashDepositedInTrustAccountPerUnit	10.2
CY2023Q4	us-gaap	Fair Value Investments Entities That Calculate Net Asset Value Per Share Redemption Restriction Percentage FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareRedemptionRestrictionPercentage	0.80	pure
CY2023Q4	cero	Redemption Value Per Share RedemptionValuePerShare	10.2
CY2023Q4	us-gaap	Minimum Net Worth Required For Compliance MinimumNetWorthRequiredForCompliance	5000001	usd
CY2023Q2	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	150000	usd
CY2023Q3	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	37052	usd
CY2023Q3	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	8846	usd
CY2023Q3	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	22949	usd
CY2023Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	22949	usd
CY2023Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	22949	usd
CY2023Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	22949	usd
CY2023Q4	cero	Payments For Accrual Of Interest In Trust Account PaymentsForAccrualOfInterestInTrustAccount	8400000	usd
CY2023	us-gaap	Disposal Group Including Discontinued Operation Interest Expense DisposalGroupIncludingDiscontinuedOperationInterestExpense	100000	usd
CY2023Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	10.2
CY2023	us-gaap	Other Payments To Acquire Businesses OtherPaymentsToAcquireBusinesses	50000000	usd
CY2023	cero	Additional Units Issued During Period Shares New Issues AdditionalUnitsIssuedDuringPeriodSharesNewIssues	2200000	shares
CY2023Q4	us-gaap	Preferred Stock Liquidation Preference PreferredStockLiquidationPreference	10
CY2022Q3	cero	Percentage Of Excise Tax PercentageOfExciseTax	0.01	pure
CY2023	cero	Percentage Of Excise Tax PercentageOfExciseTax	0.01	pure
CY2023Q3	us-gaap	Common Stock Shares Held In Employee Trust Shares CommonStockSharesHeldInEmployeeTrustShares	523341	shares
CY2023Q3	us-gaap	Proceeds From Sale And Maturity Of Other Investments ProceedsFromSaleAndMaturityOfOtherInvestments	5638879	usd
CY2023Q4	us-gaap	Sales And Excise Tax Payable Current And Noncurrent SalesAndExciseTaxPayableCurrentAndNoncurrent	56389	usd
CY2023	us-gaap	Deposit Liabilities Other Average Rate Paid DepositLiabilitiesOtherAverageRatePaid	0.01	pure
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	96873	usd
CY2023Q4	us-gaap	Assets Held In Trust Current AssetsHeldInTrustCurrent	8436311	usd
CY2023Q4	cero	Net Working Capital NetWorkingCapital	5049122	usd
CY2023Q2	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	182308	usd
CY2023Q4	us-gaap	Retained Earnings Appropriated RetainedEarningsAppropriated	14200000	usd
CY2023	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Reclassifications</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior year amounts have been reclassified due to an immaterial correction of an error and for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations. An adjustment for $244,777 has been made to Class A common stock subject to possible redemption and Accumulated deficit as of December 31, 2022 to correct the total amount redeemable to stockholders.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In the Form 10-Q for three months ended March 31, 2023, the Company discovered an error in the Statement of Cash Flows for the presentation of restricted cash. The error was not corrected and persisted in the statements of cash flows in the quarterly reports on 10-Q for the three months ended June 30, 2023 and September 30, 2023. These errors had no impact on the balance sheets or the statements of operations in those periods. This error is corrected in the statement of cash flows in the Company’s December 31, 2023 audited financial statements.</p>
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Use of Estimates</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Making estimates requires management to exercise significant judgment. Such estimates may be subject to change as more current information becomes available and accordingly the actual results could differ significantly from those estimates. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Actual results could differ from those estimates.</span></p>
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	0	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	41665974	usd
CY2023Q4	us-gaap	Cash Cash	96873	usd
CY2022Q4	us-gaap	Cash Cash	475870	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	41665974	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	96873	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	42141844	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Concentration of Credit Risk</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation coverage limit of $250,000. At December 31, 2023 and 2022, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.</span></p>
CY2023Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-94819	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-599159	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	94819	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	599159	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	607516	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	596692	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	607516	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	596692	usd
CY2023Q4	cero	Deferred Tax Expenses Capitalized Expenses Before Business Combination DeferredTaxExpensesCapitalizedExpensesBeforeBusinessCombination	607516	usd
CY2022Q4	cero	Deferred Tax Expenses Capitalized Expenses Before Business Combination DeferredTaxExpensesCapitalizedExpensesBeforeBusinessCombination	596692	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	607516	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	596692	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	607516	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	596692	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.1733	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	8.527	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0367	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	8.737	pure
CY2023Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	764957	shares
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	1288298	shares
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	178500000	usd
CY2022	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	2662553	usd
CY2022	us-gaap	Temporary Equity Other Changes TemporaryEquityOtherChanges	-167693708	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	13468845	usd
CY2023	us-gaap	Temporary Equity Other Changes TemporaryEquityOtherChanges	-5638880	usd
CY2023	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	606346	usd
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	8436311	usd
CY2021Q3	cero	Number Of Dividends NumberOfDividends	1	pure
CY2023	cero	Transfer Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination Threshold Trading Days TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays	P20D
CY2023	cero	Percentage Purchase Price PercentagePurchasePrice	0.90	pure
CY2023Q2	us-gaap	Notes And Loans Payable NotesAndLoansPayable	250000	usd
CY2023Q2	us-gaap	Notes And Loans Payable NotesAndLoansPayable	275000	usd
CY2023Q3	us-gaap	Notes And Loans Payable NotesAndLoansPayable	220000	usd
CY2023Q4	us-gaap	Notes And Loans Payable NotesAndLoansPayable	160000	usd
CY2023Q4	us-gaap	Notes And Loans Payable NotesAndLoansPayable	1555000	usd
CY2022Q4	us-gaap	Notes And Loans Payable NotesAndLoansPayable	650000	usd
CY2023	cero	Others Costs Incurred Gross OthersCostsIncurredGross	0	usd
CY2022	cero	Others Costs Incurred Gross OthersCostsIncurredGross	180000	usd
CY2023	us-gaap	Related Party Tax Expense Due To Affiliates Deferred RelatedPartyTaxExpenseDueToAffiliatesDeferred	465000	usd
CY2023	us-gaap	Noninterest Expense Investment Advisory Fees NoninterestExpenseInvestmentAdvisoryFees	1162500	usd
CY2023	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	20000	usd
CY2023	cero	Consulting Fee Incurred Under This Agreement ConsultingFeeIncurredUnderThisAgreement	200000	usd
CY2022	cero	Consulting Fee Incurred Under This Agreement ConsultingFeeIncurredUnderThisAgreement	240000	usd
CY2023Q4	us-gaap	Deposit Assets Present Value Of Expected Recoveries DepositAssetsPresentValueOfExpectedRecoveries	465000	usd
CY2023Q4	cero	Deferred Underwriting Commissions Per Unit DeferredUnderwritingCommissionsPerUnit	0.5
CY2023	us-gaap	Investment Banking Advisory Brokerage And Underwriting Fees And Commissions InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions	8750000	usd
CY2023Q4	cero	Deferred Underwriting Commissions Including Fees DeferredUnderwritingCommissionsIncludingFees	9150000	usd
CY2023Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	764957	shares
CY2022Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	1288298	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2023	cero	Notice Period To Be Given Prior To Redemption NoticePeriodToBeGivenPriorToRedemption	P30D
CY2023Q4	us-gaap	Share Price SharePrice	18
CY2024Q1	us-gaap	Deposit Assets DepositAssets	22600	usd
CY2023	us-gaap	Legal Fees LegalFees	150000	usd
CY2023	cero	Aggregate Purchase Price AggregatePurchasePrice	1500000	usd
CY2023	us-gaap	Other Expenses OtherExpenses	8540000	usd
CY2023Q4	us-gaap	Marketable Securities MarketableSecurities	25000000	usd
CY2023Q4	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	10000	shares
CY2023	cero	Percentage Of Average Daily Value Traded Of The Common Stock PercentageOfAverageDailyValueTradedOfTheCommonStock	0.60	pure
CY2023Q4	us-gaap	Advances To Affiliate AdvancesToAffiliate	20000000	usd
CY2023	cero	Percentage Of Common Stock Outstanding PercentageOfCommonStockOutstanding	0.0499	pure
CY2023Q4	us-gaap	Shares Issued SharesIssued	500000	shares
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Auditor Firm AuditorFirmId	2468
CY2022Q4	us-gaap	Assets Held In Trust Current AssetsHeldInTrustCurrent		usd
CY2023Q4	us-gaap	Assets Held In Trust AssetsHeldInTrust		usd
CY2023Q4	cero	Shareholder Redemption Liability ShareholderRedemptionLiability		usd
CY2022Q4	cero	Excise Tax Payable ExciseTaxPayable		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital		usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital		usd
CY2023	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1		usd
CY2023	us-gaap	Increase Decrease In Property And Other Taxes Payable IncreaseDecreaseInPropertyAndOtherTaxesPayable		usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2023	cero	Shareholders Redemption Liability ShareholdersRedemptionLiability		usd
CY2022	cero	Conversion Of Class B Common To Class A Common ConversionOfClassBCommonToClassACommon		usd
CY2022	cero	Excise Tax Liability Accrued For Class A Common Stock Redemptions ExciseTaxLiabilityAccruedForClassACommonStockRedemptions		usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent		usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount		usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount		usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities		usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities		usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits		usd
CY2023Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued		usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001870404

Files In Submission

Name	View Source	Status
0001213900-24-029051-index-headers.html	Edgar Link	pending
0001213900-24-029051-index.html	Edgar Link	pending
0001213900-24-029051.txt	Edgar Link	pending
0001213900-24-029051-xbrl.zip	Edgar Link	pending
cero-20231231.xsd	Edgar Link	pending
cero-20231231_cal.xml	Edgar Link	unprocessable
cero-20231231_def.xml	Edgar Link	unprocessable
ea0201955-10k_cerothera.htm	Edgar Link	pending
ea020195501ex10-13_cerothera.htm	Edgar Link	pending
ea020195501ex10-14_cerothera.htm	Edgar Link	pending
ea020195501ex10-15_cerothera.htm	Edgar Link	pending
ea020195501ex10-16_cerothera.htm	Edgar Link	pending
ea020195501ex10-17_cerothera.htm	Edgar Link	pending
ea020195501ex19-1_cerothera.htm	Edgar Link	pending
ea020195501ex21-1_cerothera.htm	Edgar Link	pending
ea020195501ex3-6_cerothera.htm	Edgar Link	pending
ea020195501ex31-1_cerothera.htm	Edgar Link	pending
ea020195501ex31-2_cerothera.htm	Edgar Link	pending
ea020195501ex32-1_cerothera.htm	Edgar Link	pending
ea020195501ex4-5_cerothera.htm	Edgar Link	pending
ea020195501ex97-1_cerothera.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
image_003.jpg	Edgar Link	pending
image_004.jpg	Edgar Link	pending
image_005.jpg	Edgar Link	pending
image_006.jpg	Edgar Link	pending
image_007.jpg	Edgar Link	pending
image_008.jpg	Edgar Link	pending
image_009.jpg	Edgar Link	pending
image_010.jpg	Edgar Link	pending
image_011.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
cero-20231231_lab.xml	Edgar Link	unprocessable
ea0201955-10k_cerothera_htm.xml	Edgar Link	completed
cero-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CERO
CERo Therapeutics Holdings Inc Stock $cero

2024 Q2 Form 10-K Financial Statement

#000121390024029051 Filed on April 02, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CERO CERo Therapeutics Holdings Inc Stock $cero

2024 Q2 Form 10-K Financial Statement

#000121390024029051 Filed on April 02, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CERO
CERo Therapeutics Holdings Inc Stock $cero